Philadelphia, PANCT06396533Now EnrollingIRB Ready

Urothelial Carcinoma Clinical Trial in Philadelphia, PA

Access cutting-edge urothelial carcinoma treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Fox Chase Cancer Center

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access urothelial carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related urothelial carcinoma treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this urothelial carcinoma clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Urothelial Carcinoma Study in Philadelphia

This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy. Patients who are planned for cystectomy due to bladder cancer will be considered for enrollment based on inclusion and exclusion criteria.

Sponsor: Fox Chase Cancer Center

Who Can Participate

Inclusion Criteria

Properly counselled patients with high grade T1 disease who elect for cystectomy
Properly counselled patients with non-muscle invasive high grade Ta urothelial carcinoma or carcinoma in situ who are unresponsive to intravesical therapy and have elected cystectomy
cT2-T3 muscle invasive urothelial carcinoma for planned cystectomy
Patient who have received prior intravesical therapy or multiple TURBTs can be enrolled (data regarding number of previous TURBTs and type of intravesical therapy will be collected).
Male or female patients age \>=18 years at the time of consent.
Able and willing to comply with study requirements.
Patients must have a non-contrast phase component for CT scans of chest/abdomen/pelvis either pre-existing (prior to accrual) or obtained during the screening process.
Patients who undergo neoadjuvant systemic therapy for muscle invasive disease must be enrolled before starting systemic therapy.
Ability to understand and willingness to sign a written informed consent and HIPAA authorization document.

Exclusion Criteria

Patients who undergo cystectomy with non-curative intent will be excluded.
Patients who have undergone previous definitive pelvic radiation for the purpose of treating bladder malignancy.
Patients who are pregnant or nursing.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT06396533) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Urothelial Carcinoma Treatment Options in Philadelphia, PA

If you're searching for urothelial carcinoma treatment options in Philadelphia, PA, this clinical trial (NCT06396533) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced urothelial carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all urothelial carcinoma clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Philadelphia, PA

See all bladder cancer clinical trials recruiting in Philadelphia — not just this study.

Browse Bladder Cancer Trials in Philadelphia →

Browse More Trials by Condition

Bladder Cancer TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA